Cerus Corp (CERS)

$1.655

-0.02

(-1.49%)▲

Live

Insights on Cerus Corp

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 30.97M → 46.76M (in $), with an average increase of 12.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -15.64M → -1.32M (in $), with an average increase of 182.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 34.4% return, outperforming this stock by 66.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 133.9%

Performance

  • $1.65
    $1.71
    $1.66
    downward going graph

    0.6%

    Downside

    Day's Volatility :3.23%

    Upside

    2.64%

    downward going graph
  • $1.21
    $3.08
    $1.66
    downward going graph

    27.11%

    Downside

    52 Weeks Volatility :60.71%

    Upside

    46.1%

    downward going graph

Returns

PeriodCerus CorpSector (Health Care)Index (Russel 2000)
3 Months
-6.67%
1.9%
0.0%
6 Months
24.44%
10.7%
0.0%
1 Year
-31.71%
4.6%
-1.1%
3 Years
-72.84%
14.2%
-22.1%

Highlights

Market Capitalization
306.4M
Book Value
$0.29
Earnings Per Share (EPS)
-0.21
PEG Ratio
0.0
Wall Street Target Price
4.3
Profit Margin
-23.98%
Operating Margin TTM
2.09%
Return On Assets TTM
-7.91%
Return On Equity TTM
-61.71%
Revenue TTM
156.4M
Revenue Per Share TTM
0.87
Quarterly Revenue Growth YOY
6.2%
Gross Profit TTM
87.1M
EBITDA
-23.7M
Diluted Eps TTM
-0.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.1
EPS Estimate Next Year
-0.06
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Cerus Corp(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 159.82%

Current $1.66
Target $4.30

Company Financials

FY18Y/Y Change
Revenue
60.9M
↑ 39.8%
Net Income
-57.6M
↓ 4.99%
Net Profit Margin
-94.51%
↑ 44.55%
FY19Y/Y Change
Revenue
74.6M
↑ 22.56%
Net Income
-71.2M
↑ 23.76%
Net Profit Margin
-95.44%
↓ 0.93%
FY20Y/Y Change
Revenue
91.9M
↑ 23.14%
Net Income
-59.9M
↓ 15.98%
Net Profit Margin
-65.12%
↑ 30.32%
FY21Y/Y Change
Revenue
130.9M
↑ 42.36%
Net Income
-54.4M
↓ 9.16%
Net Profit Margin
-41.55%
↑ 23.57%
FY22Y/Y Change
Revenue
162.0M
↑ 23.83%
Net Income
-42.8M
↓ 21.24%
Net Profit Margin
-26.43%
↑ 15.12%
FY23Y/Y Change
Revenue
156.4M
↓ 3.51%
Net Income
-37.5M
↓ 12.46%
Net Profit Margin
-23.98%
↑ 2.45%
Q3 FY22Q/Q Change
Revenue
39.6M
↓ 3.48%
Net Income
-8.5M
↑ 1.5%
Net Profit Margin
-21.53%
↓ 1.05%
Q4 FY22Q/Q Change
Revenue
44.0M
↑ 11.28%
Net Income
-13.6M
↑ 59.9%
Net Profit Margin
-30.94%
↓ 9.41%
Q1 FY23Q/Q Change
Revenue
31.0M
↓ 29.66%
Net Income
-15.6M
↑ 14.8%
Net Profit Margin
-50.5%
↓ 19.56%
Q2 FY23Q/Q Change
Revenue
38.9M
↑ 25.44%
Net Income
-13.3M
↓ 15.13%
Net Profit Margin
-34.17%
↑ 16.33%
Q3 FY23Q/Q Change
Revenue
39.8M
↑ 2.37%
Net Income
-7.3M
↓ 45.26%
Net Profit Margin
-18.27%
↑ 15.9%
Q4 FY23Q/Q Change
Revenue
46.8M
↑ 17.59%
Net Income
-1.3M
↓ 81.73%
Net Profit Margin
-2.84%
↑ 15.43%
FY18Y/Y Change
Total Assets
163.5M
↑ 66.38%
Total Liabilities
78.9M
↑ 33.11%
FY19Y/Y Change
Total Assets
165.5M
↑ 1.27%
Total Liabilities
108.5M
↑ 37.42%
FY20Y/Y Change
Total Assets
221.4M
↑ 33.76%
Total Liabilities
117.6M
↑ 8.41%
FY21Y/Y Change
Total Assets
237.5M
↑ 7.26%
Total Liabilities
151.9M
↑ 29.14%
FY22Y/Y Change
Total Assets
218.1M
↓ 8.17%
Total Liabilities
149.5M
↓ 1.55%
FY23Y/Y Change
Total Assets
197.7M
↓ 9.33%
Total Liabilities
144.3M
↓ 3.49%
Q3 FY22Q/Q Change
Total Assets
215.4M
↓ 0.49%
Total Liabilities
141.3M
↑ 1.17%
Q4 FY22Q/Q Change
Total Assets
218.1M
↑ 1.25%
Total Liabilities
149.5M
↑ 5.8%
Q1 FY23Q/Q Change
Total Assets
209.3M
↓ 4.01%
Total Liabilities
149.8M
↑ 0.16%
Q2 FY23Q/Q Change
Total Assets
198.9M
↓ 5.0%
Total Liabilities
147.2M
↓ 1.74%
Q3 FY23Q/Q Change
Total Assets
205.8M
↑ 3.51%
Total Liabilities
156.8M
↑ 6.56%
Q4 FY23Q/Q Change
Total Assets
197.7M
↓ 3.93%
Total Liabilities
144.3M
↓ 7.98%
FY18Y/Y Change
Operating Cash Flow
-31.2M
↓ 40.18%
Investing Cash Flow
-43.8M
↓ 10515.2%
Financing Cash Flow
92.8M
↑ 115.7%
FY19Y/Y Change
Operating Cash Flow
-65.8M
↑ 110.71%
Investing Cash Flow
28.2M
↓ 164.28%
Financing Cash Flow
43.5M
↓ 53.11%
FY20Y/Y Change
Operating Cash Flow
-40.7M
↓ 38.12%
Investing Cash Flow
-49.6M
↓ 275.83%
Financing Cash Flow
91.8M
↑ 111.06%
FY21Y/Y Change
Operating Cash Flow
-33.9M
↓ 16.74%
Investing Cash Flow
12.7M
↓ 125.6%
Financing Cash Flow
34.3M
↓ 62.64%
FY22Y/Y Change
Operating Cash Flow
-25.6M
↓ 24.49%
Investing Cash Flow
8.5M
↓ 33.29%
Financing Cash Flow
4.2M
↓ 87.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.1M
↑ 496.52%
Investing Cash Flow
-2.1M
↓ 62.26%
Financing Cash Flow
1.1M
↑ 436.63%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.8M
↓ 14.67%
Investing Cash Flow
7.4M
↓ 457.36%
Financing Cash Flow
457.0K
↓ 57.84%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.5M
↑ 384.05%
Investing Cash Flow
-1.6M
↓ 122.29%
Financing Cash Flow
2.1M
↑ 350.98%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.0M
↑ 5.84%
Investing Cash Flow
2.3M
↓ 241.49%
Financing Cash Flow
-173.0K
↓ 108.39%

Technicals Summary

Sell

Neutral

Buy

Cerus Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cerus Corp
Cerus Corp
-4.0%
24.44%
-31.71%
-72.84%
-72.14%
Stryker Corporation
Stryker Corporation
-4.59%
26.35%
10.88%
26.25%
80.99%
Boston Scientific Corp.
Boston Scientific Corp.
2.53%
35.38%
34.38%
63.21%
94.67%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.81%
24.49%
-1.17%
-8.62%
48.12%
Abbott Laboratories
Abbott Laboratories
-2.2%
13.48%
-2.55%
-12.23%
40.18%
Medtronic Plc
Medtronic Plc
-2.34%
12.97%
-9.37%
-37.53%
-5.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cerus Corp
Cerus Corp
NA
NA
0.0
-0.1
-0.62
-0.08
NA
0.29
Stryker Corporation
Stryker Corporation
39.67
39.67
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.57
63.57
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.15
38.15
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.36
33.36
5.99
4.61
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.58
25.58
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cerus Corp
Cerus Corp
Buy
$306.4M
-72.14%
NA
-23.98%
Stryker Corporation
Stryker Corporation
Buy
$124.7B
80.99%
39.67
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.0B
94.67%
63.57
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.8B
48.12%
38.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$185.8B
40.18%
33.36
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.0B
-5.08%
25.58
13.0%

Institutional Holdings

  • ARK Investment Management LLC

    11.54%

  • Baker Bros Advisors LP

    10.74%

  • BlackRock Inc

    7.57%

  • Vanguard Group Inc

    5.44%

  • PRIMECAP Management Company

    4.75%

  • Sumitomo Mitsui Trust Holdings Inc

    4.28%

Corporate Announcements

  • Cerus Corp Earnings

    Cerus Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.

Organization
Cerus Corp
Employees
625
CEO
Mr. William M. Greenman
Industry
Health Technology

Discover More

FAQs